Treatment of spastic esophageal motility disorders.
Treatment of spastic motility disorders continues to be challenging. Therapeutic options remain limited due in part to our lack of understanding of the pathophysiology and significance of these disorders. Furthermore, most of therapeutic trials to date are hampered by the poorly designed nature of the study, including the small size of the trials and the lack of placebo arm. Most of the available information suggests that there seems to be an important dissociation between symptoms (chest pain/dysphagia) and esophageal dysmotility. Drug treatment aimed at visceral sensitivity seems more effective in relieving symptoms than spasmolytic medications. Recent trials with Botox, nitric oxide derivatives, and SSRIs offer promising results. Rigorous study design that includes large placebo-controlled trials is needed in this area.
Achem
Sami R
SR
Department of Gastroenterology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Achem.Sami@Mayo.edu
D002637:Chest Pain / Q000209:etiology / Q000628:therapy*; D015154:Esophageal Motility Disorders / Q000188:drug therapy*; D006801:Humans; D006930:Hyperalgesia / Q000188:drug therapy / Q000503:physiopathology; D010465:Perception / Q000502:physiology; D011619:Psychotropic Drugs / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014781:Viscera / Q000503:physiopathology
D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors